AbbVie Inc. has applied for U.S. approval of a new treatment for hepatitis C.
The North Chicago-based drugmaker said Tuesday testing of the new drug involved more than 2,300 patients in 25 countries. AbbVie expects to seek approval in the European Union in May.
“This (New Drug Application) submission is a significant advancement for AbbVie’s HCV development program,” said Dr. Scott Brun, the company’s vice president of pharmaceutical development. “We believe our all-oral, interferon-free regimen holds the potential to be a promising new therapy for patients living with this chronic infection.”
The company says about 3.2 million people in the U.S. live with the hepatitis C virus.
$ABBV’s NDA in the US for its investigational #HCV regimen represents a milestone for the company http://t.co/w2sirqqHt1
— AbbVie (@abbvie) April 22, 2014
AbbVie to move 2,000 employees off North Chicago campus
